71 – 80 of 161
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk : The GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol
- Contribution to journal › Article
-
Mark
Identification of infants with increased type 1 diabetes genetic risk for enrollment into Primary Prevention Trials—GPPAD-02 study design and first results
- Contribution to journal › Article
-
Mark
Autoantibodies in Pandemrix®-induced narcolepsy : Nine candidate autoantigens fail the conformational autoantibody test
- Contribution to journal › Article
-
Mark
Eleven Amino Acids of HLA-DRB1 and Fifteen Amino Acids of HLA-DRB3, 4 and 5 Include Potentially "Causal Residues" Responsible for the Risk of Childhood Type 1 Diabetes
- Contribution to journal › Article
-
Mark
Metabolite-related dietary patterns and the development of islet autoimmunity
- Contribution to journal › Article
-
Mark
Who is enrolling? The path to monitoring in type 1 diabetes trialnet’s pathway to prevention
- Contribution to journal › Article
-
Mark
HLA high-resolution typing by next-generation sequencing in Pandemrix-induced narcolepsy
- Contribution to journal › Article
- 2018
-
Mark
Safety and efficacy of autoantigen-specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes : A randomized clinical trial
- Contribution to journal › Article
-
Mark
Gestational respiratory infections interacting with offspring HLA and CTLA-4 modifies incident β-cell autoantibodies
- Contribution to journal › Article
-
Mark
Pandemrix® vaccination is not associated with increased risk of islet autoimmunity or type 1 diabetes in the TEDDY study children
- Contribution to journal › Article
